In this study, we sought to determine if AKT inhibition in combination with IM could be an effective strategy in less IM-sensitive models, including an established PDX GIST model which possesses an exon 9 KIT mutation. This evidence concerns the gene AKT1 and gastrointestinal stromal tumor.